GoodRx Holdings (GDRX) Interest Expenses (2019 - 2026)

For the trailing twelve months through Jun 30, 2026, Interest Expenses at GoodRx Holdings was $40.81 million, down 9.5% year-over-year; for FY2025, it was $42.61 million, down 19.5% from FY2024.

• Annual Interest Expenses shows a five-year compound annual growth rate of 8.8% (FY2020 to FY2025).
• In prior years, GoodRx Holdings' Interest Expenses was $52.92 million in FY2024 (-6.7%), $56.73 million in FY2023 (+65.7%), $34.24 million in FY2022 (+44.8%) and $23.64 million in FY2021 (-15.3%).
• Quarterly Interest Expenses has run from a low of $5.87 million in Q1 2022 to a high of $14.82 million in Q4 2023 over five years.
• On a year-over-year basis, Interest Expenses has declined in each of the last eight quarters, with an average decline of 16.3% over the last eight quarters.
• The strongest year-over-year quarter for Interest Expenses in the past five years was Q1 2023, with growth of 123.8%; the weakest was Q1 2025, with a decline of 27.3%.
• According to Business Quant data, Interest Expenses for the three prior quarters was $9.77 million (Q1 2026), $10.4 million (Q4 2025) and $10.83 million (Q3 2025).